logo
Plus   Neg
Share
Email

Santarus Adds FENOGLIDE To Marketed Products Portfolio

Santarus, Inc. (SNTS) said Wednesday that it has entered into an exclusive license agreement with Shore Therapeutics, Inc. to commercialize FENOGLIDE Tablets 40 mg and 120 mg in the U.S.

FENOGLIDE is indicated as an adjunct to diet to reduce elevated low-density lipoprotein-cholesterol, total cholesterol, triglycerides and apolipoprotein B, and to increase high-density lipoprotein-cholesterol in adult patients with primary hyperlipidemia or mixed dyslipidemia. FENOGLIDE also is indicated as an adjunct to diet for treatment of adult patients with hypertriglyceridemia.

FENOGLIDE has U.S. sales of $8.7 million for the 12 months ended October 31, according to IMS Health. FENOGLIDE was previously promoted by Shionogi Pharma, Inc. from February 2008 to August 2010 and according to IMS Health achieved peak U.S. sales of approximately $23 million for the 12 months ended August 31, 2010. Shore Therapeutics subsequently promoted FENOGLIDE through a small part-time contract sales force.

Under the terms of the license agreement, Santarus will pay Shore an $11 million upfront fee and tiered royalties on net sales of FENOGLIDE.

Santarus also will have to pay one-time, success-based milestones of $2 million if calendar year net sales equal or exceed $20 million and $3 million if calendar year net sales equal or exceed $30 million.

Additionally, Santarus affirmed its financial outlook for 2011, which calls for revenue of at least $115 million and net income of bout $3 million. Analysts polled by Thomson Reuters currently expect the company to earn $0.07 per share on revenue of $116.49 million for the full year 2011.

Santarus also introduced its financial outlook for full year 2012, saying it expects revenue of about $200 million and net income of $8 million to $11 million. Analysts currently expect the company to earn $0.25 per share on revenue of $178.56 million for 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Every month new phones flood the market, so your head may be spinning when trying to decide which one to buy. Let's take a look at the best smartphone available right now. 1. Samsung Galaxy S9/S9 Plus: Samsung' recently launched flagship device the Galaxy S9 and S9 Plus is the best android smartphone... General Electric Co (GE) reported first-quarter consolidated adjusted EPS of $0.16 compared to $0.14, prior year. Adjusted EPS rose 14% with strong performance in Aviation, Healthcare, Renewables, Transportation, & Corporate partly offset by lower Power, Oil & Gas, & GE Capital earnings. First-quarter... Each year, more than eight million children die from preventable diseases in countries with the worst health care systems . Kofi Annan, former head of the UN, said that, "Almost all these deaths will happen in developing countries. A large number of them could be prevented." You do not want to find...
Follow RTT